EC Number   |
Inhibitors |
Structure  |
|---|
    2.6.1.19 | more |
no inhibition by 6-azauridine, 6-azauridine 5'-phosphate, uracil, (iso)orotic acid, cytosine, thymine, dihydrothymine, 2-thiocytosine, thiourea; not inhibitory: 5-aminouracil |
 |
| 2.6.1.19 | more |
- |
|
| 2.6.1.19 | more |
no inhibition by 3-aminopropane-1-sulfonic acid, isoguvacine (i.e. 1,2,3,4-tetrahydro-1-methyl-3-pyridine carboxylic acid), baclofen (i.e. beta-(aminomethyl)-4-chlorobenzenepropanoic acid), bicuculline, picrotoxin, Schistocerca gregaria: antiserum against sheep enzyme |
|
| 2.6.1.19 | more |
no inhibition by chelating agents, non-substrate L- or D-amino acids, metal ions |
|
| 2.6.1.19 | more |
no substrate inhibition: 4-aminobutanoate |
|
| 2.6.1.19 | more |
(+/-)-(1S,3S,4S)-3-amino-4-fluorocyclohexanecarboxylic acid and (cis)-3-amino-5,5-difluorocylcohexanecarboxylic acid are no an inhibitors of GABA-AT at a concentration of 10 mM |
|
| 2.6.1.19 | more |
the methanol extract from Melissa officinalis is a potent in vitro inhibitor of GABA-T with IC50 of 0.55 mg/ml, inhibition decreases in the order: methanol extract, water extract, ethyl acetate extract and hexane extract (not inhibitory) |
|
| 2.6.1.19 | more |
a series of gamma-aminobutyric acid (GABA) derivatives obtained from 4-(1,3-dioxoisoindolin-2-yl)butanoic acid are synthesized and analyzed as inhibitory ligands docking against human ABAT as well as pig ABAT receptors. Active site docking study, overview |
|
| 2.6.1.19 | more |
molecular dynamics simulations, design of mechanism-based inhibitors, drug design, overview |
|
| 2.6.1.19 | ATP |
reversible |
  |
